<div id="readability-page-1"><p>Abbott Laboratories (NYSE:ABT - Get Free Report) updated its second quarter 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 1.230-1.270 for the period, compared to the consensus earnings per share estimate of 1.250. The company issued revenue guidance of -. Abbott Laboratories also updated its FY 2025 guidance to 5.050-5.250 EPS.</p><div><p><span></span><span>Get <strong>Abbott Laboratories</strong> alerts:</span></p></div><h2>Abbott Laboratories Stock Performance</h2><ul><li>Abbott Laboratories Will Outperform Healthcare Stocks in 2025</li></ul><p>Shares of Abbott Laboratories stock opened at $131.09 on Wednesday. Abbott Laboratories has a 1-year low of $99.71 and a 1-year high of $141.23. The company has a 50 day moving average of $130.62 and a 200-day moving average of $121.54. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The company has a market cap of $227.35 billion, a PE ratio of 17.32, a price-to-earnings-growth ratio of 2.52 and a beta of 0.80. </p><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, beating the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.38 billion.  As a group, equities research analysts forecast that  Abbott Laboratories will post 5.14 earnings per share for the current fiscal year. </p><h2>Abbott Laboratories Dividend Announcement</h2><ul><li>These Are The Top Health Stocks to Own for Buy-and-Hold Investing</li></ul><p>The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be issued a dividend of $0.59 per share. The ex-dividend date is Tuesday, April 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.80%. Abbott Laboratories's dividend payout ratio (DPR) is presently 30.85%. </p><h2>Analyst Ratings Changes</h2><p>A number of brokerages have recently issued reports on ABT. Barclays  restated an &#34;overweight&#34; rating and set a $158.00 price objective (up from $149.00) on shares of Abbott Laboratories in a research report on Monday, January 27th. Royal Bank of Canada  restated an &#34;outperform&#34; rating and issued a $135.00 target price on shares of Abbott Laboratories in a report on Tuesday, January 21st. StockNews.com lowered Abbott Laboratories from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Wednesday, February 12th. Citigroup increased their price target on Abbott Laboratories from $135.00 to $160.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, March 4th. Finally, Stifel Nicolaus upped their target price on shares of Abbott Laboratories from $130.00 to $135.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, January 23rd. Four investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one  has issued  a strong buy rating to the company. According to MarketBeat, Abbott Laboratories presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $137.94.</p><ul><li>MarketBeat Week in Review – 10/14 - 10/18</li></ul><p><b>Get Our Latest Stock Analysis on Abbott Laboratories</b></p><h2>Insider Buying and Selling at Abbott Laboratories</h2><p>In other news, SVP Eric Shroff sold 562 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total transaction of $77,651.54. Following the transaction, the senior vice president now directly owns 31,970 shares of the company's stock, valued at approximately $4,417,294.90. This trade represents a 1.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Andrea F. Wainer sold 949 shares of Abbott Laboratories stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total value of $131,123.33. Following the sale, the executive vice president now directly owns 74,381 shares of the company's stock, valued at approximately $10,277,222.77. This trade represents a 1.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 116,449 shares of company stock worth $15,463,316 over the last quarter. Insiders own  0.46% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>A hedge fund recently raised its stake in Abbott Laboratories stock. Brighton Jones LLC raised its position in  Abbott Laboratories (NYSE:ABT - Free Report) by 10.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 51,719 shares of the healthcare product maker's stock after buying an additional 4,755 shares during the period. Brighton Jones LLC's holdings in Abbott Laboratories were worth $5,850,000 at the end of the most recent reporting period. 75.18% of the stock is owned by institutional investors and hedge funds. </p><h2>About Abbott Laboratories</h2> (Get Free Report)<p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Abbott Laboratories</li><li>What Are Trending Stocks? Trending Stocks Explained</li><li>Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit</li><li>Special Purpose Acquisition Company (SPAC) What You Need to Know </li><li>XPO Buying $50 Million of Its Own Stock: Here's Why </li><li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li><li>Tesla Stock Eyes Breakout With Earnings on Deck</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2><p>Before you consider Abbott Laboratories, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Abbott Laboratories (NYSE:ABT) has updated its Q2 2025 earnings guidance, projecting EPS between 1.230 and 1.270, slightly below the consensus estimate of 1.250. The company also revised its FY 2025 EPS guidance to 5.050-5.250. Abbott's stock opened at $131.09, with a market cap of $227.35 billion and a PE ratio of 17.32. Recent analyst ratings show a consensus of "Moderate Buy" with an average price target of $137.94. The company declared a quarterly dividend of $0.59 per share, payable on May 15th.</p>

Abbott Laboratories (NYSE:ABT) Issues Q2 2025 Earnings Guidance